Julie Li

US Patent:

8399646, Mar 19, 2013

Filed:

Sep 2, 2011

Appl. No.:

13/225119

Inventors:

Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Yuli Wang - San Diego CA, US

Assignee:

Rinat Neuroscience Corp. - South San Francisco CA
Pfizer Inc. - New York NY

International Classification:

C07H 21/04
C12P 21/08
C12N 5/07

US Classification:

536 2353, 435 691, 435326, 435329

Abstract:

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

US Patent:

8426363, Apr 23, 2013

Filed:

Sep 2, 2011

Appl. No.:

13/225265

Inventors:

Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Yuli Wang - San Diego CA, US

Assignee:

Rinat Neuroscience Corp. - South San Francisco CA
Pfizer Inc. - New York NY

International Classification:

A61P 3/06
A61K 38/00

US Classification:

514 74, 4241301, 4241311

Abstract:

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

US Patent:

20100068199, Mar 18, 2010

Filed:

Sep 11, 2009

Appl. No.:

12/558312

Inventors:

Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Xiayang Qiu - Mystic CT, US
Pavel Strop - San Mateo CA, US
Yuli Wang - San Diego CA, US

International Classification:

A61K 39/395
C07K 16/00
C12N 5/10
C07H 21/04
A61P 9/00

US Classification:

4241301, 5303891, 5303873, 5303879, 435325, 536 2353

Abstract:

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

US Patent:

20130273069, Oct 17, 2013

Filed:

Apr 4, 2013

Appl. No.:

13/857063

Inventors:

Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Julie Jia Li HAWKINS - Weston CT, US
Jaume PONS - San Francisco CA, US
Xiayang QIU - Mystic CT, US
Pavel STROP - San Mateo CA, US
Yuli WANG - San Diego CA, US

International Classification:

C07K 16/40
A61K 45/06
A61K 39/395

US Classification:

4241581, 5303891, 5303879, 5303873

Abstract:

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

US Patent:

20160096898, Apr 7, 2016

Filed:

Sep 24, 2015

Appl. No.:

14/864750

Inventors:

- South San Francisco CA, US
- New York NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Julie Jia Li HAWKINS - Weston CT, US
Jaume PONS - San Francisco CA, US
Xiayang QIU - Mystic CT, US
Pavel STROP - San Mateo CA, US
Yuli WANG - San Diego CA, US

Assignee:

PFIZER INC. - New York NY
RINAT NEUROSCIENCE CORP. - South San Francisco CA

International Classification:

C07K 16/40

Abstract:

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.